ストックスクリーナーアプリを入手
21.17
10.09%
1.94
前日終値:
$19.23
開ける：
$19.21
24時間の取引高:
397.08K
Relative Volume:
0.66
時価総額：
$400.78M
収益：
当期純損益:
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
1週間 パフォーマンス:
+30.60%
1か月 パフォーマンス:
-28.82%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$15.37
$21.33
52週間の値動き範囲:
$13.50
$39.60
Scribe Therapeutics Inc. Common Stock Stock (SCTX) Company Profile
Compare SCTX vs VRTX, MRNA, REGN, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SCTX
Scribe Therapeutics Inc. Common Stock
|
21.17 | 400.78M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
508.89 | 128.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
212.54 | 84.85B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
765.84 | 78.85B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
818.91 | 51.50B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
192.94 | 41.36B | 742.00K | -1.37B | -1.07B | -7.0731 |
Scribe Therapeutics Inc. Common Stock Stock (SCTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-08-31 | 開始されました | H.C. Wainwright | Buy |
| 2026-08-18 | 開始されました | Guggenheim | Buy |
| 2026-08-18 | 開始されました | Leerink Partners | Outperform |
| 2026-08-18 | 開始されました | Wells Fargo | Overweight |
Scribe Therapeutics Inc. Common Stock (SCTX) 最新ニュース
Scribe Therapeutics Inc. Common Stock (NASDAQ: SCTX) Stock Price, News & Analysis - kalkine.ca
Scribe Therapeutics Inc. Common Stock (NASDAQ: SCTX) Stock Price, News & Analysis - Kalkine
Scribe Therapeutics (SCTX) awards 14,725 stock options to director Bleharski - Stock Titan
OrbiMed Advisors Discloses Investment in Scribe Therapeutics with 7.2% Stake - TradingView
Scribe Therapeutics Completes Initial Public Offering and Private Placement - SynBioBeta
Scribe Therapeutics raises $155.51M in IPO on Nasdaq By Investing.com - Investing.com India
Avoro lifts Scribe (NASDAQ: SCTX) stake to 3.09M shares - Stock Titan
Latham Advises on Scribe Therapeutics’ US$155.51 Million IPO - Legal Desire
Latham Advises on Scribe Therapeutics’ US$155.51 Million IPO - Latham & Watkins LLP
Scribe Therapeutics IPO closes as Sanofi buys 500K shares - Stock Titan
Scribe Therapeutics, In Vivo CRISPR Genetic Medicines, Files for Nasdaq IPO - TradingView
Scribe Therapeutics Announces Closing of Initial Public - GlobeNewswire
Scribe Therapeutics Closes Upsized $155.5 Million IPO and Concurrent Private Placement with Sanofi - Quiver Quantitative
Scribe Therapeutics closes $155.5M IPO at $15 per share - Investing.com
Scribe Therapeutics raises $155.51M in IPO on Nasdaq - Investing.com
Scribe Therapeutics raises $155.51M in IPO on Nasdaq By Investing.com - Investing.com Nigeria
Scribe Therapeutics (SCTX) CFO gets major option grants and family share buys - Stock Titan
Scribe Therapeutics (SCTX) awards 14,725 stock options to director James Dean Watson - Stock Titan
Scribe Therapeutics (SCTX) grants 14,725 options to Aghazadeh and Avoro entities - Stock Titan
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement - Yahoo Finance
Scribe Therapeutics (SCTX) CEO receives time- and performance-based option grants - Stock Titan
Scribe Therapeutics prices IPO at $15 per share on Nasdaq By Investing.com - Investing.com UK
IPO calendar for: - Yahoo Finance Singapore
Scribe Therapeutics prices IPO at $15 per share on Nasdaq By Investing.com - Investing.com Nigeria
Scribe Therapeutics Prices Upsized $128.7 Million Initial Public Offering and Concurrent Private Placement to Sanofi - quiverquant.com
Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech - BioSpace
Scribe Therapeutics Inc. (SCTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Scribe Therapeutics (Nasdaq:SCTX)Stock Analysis - Simply Wall Street
Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering - GlobeNewswire
Scribe Therapeutics prices IPO at $15 per share on Nasdaq - Investing.com
Scribe Therapeutics Inc. has completed an IPO in the amount of $128.7 million. - marketscreener.com
Scribe Therapeutics prices IPO at $15, to raise $128.7M - Investing.com
Sanofi Agrees to Buy 500,000 Scribe Shares in a Private Placement - Stock Titan
Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering - Yahoo Finance
Scribe Therapeutics Starts IPO Effort For CRISPR Pipeline Development (SCTX) - Seeking Alpha
Scribe Therapeutics files for 7.15M share IPO at $13-$15/sh - Investing.com
Scribe Therapeutics files for 7.15M share IPO at $13-$15/sh - Investing.com Nigeria
Scribe Therapeutics files for 7.15M share IPO at $13-$15/sh - Investing.com UK
Scribe Therapeutics Inc. Common Stock (SCTX) 財務データ
Scribe Therapeutics Inc. Common Stock (SCTX) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Scribe Therapeutics Inc. Common Stock (SCTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Aghazadeh Behzad | Director |
Jul 28 '26 |
Buy |
18.25 |
7,905 |
144,266 |
3,088,888 |
| GORDON CARL L | Director |
Jul 27 '26 |
Buy |
15.00 |
1,000,000 |
15,000,000 |
1,348,825 |
| ORBIMED ADVISORS LLC | Director |
Jul 27 '26 |
Buy |
15.00 |
1,000,000 |
15,000,000 |
1,348,825 |
| Aghazadeh Behzad | Director |
Jul 24 '26 |
Buy |
15.15 |
2,383,333 |
36,115,495 |
3,080,983 |
| Lucas Svetlana | Chief Business Officer |
Jul 23 '26 |
Buy |
15.00 |
3,000 |
45,000 |
3,000 |
| Parrot David | Chief Financial Officer |
Jul 23 '26 |
Buy |
15.00 |
2,666 |
39,990 |
1,333 |
1.06%
大文字化:
|
ボリューム (24 時間):